2 and 3 ; all improvements were highly significant ( p < 0.0001) and similar for questions related to pain and functional activities (mean improvement of 44%) and to sleep and mental symptoms (mean improvement of 40%) (Table 2 ).
In a recent trial, Belczak and colleagues [ 26 ] studied the effects of different veno-active drugs on limb volume reduction, tibiotarsal range of motion, and QoL in 136 patients with CVD; a 30-day treatment with diosmin plus hesperidin (450 and 50 mg), or aminaphtone (75 mg), or coumarin plus troxerutin (15 and 90 mg) or placebo every 12 h showed a significant improvement in QoL (a) versus baseline in the aminaphtone and diosmin plus hesperidin treatment groups and (b) versus placebo only in the aminaphtone group ( p = 0.007), while in the diosmin plus hesperidine group the improvement tended toward significance ( p = 0.055).